ClinicalTrials.gg
SuspendedNCT03616236Updated Nov 12, 2026

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

A Phase 3 interventional study of Buprenorphine/Naloxone and Treatment as usual in Opioid Use, sponsored by Friends Research Institute, Inc.. Suspended at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Friends Research Institute, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was suspended
Unable to recruit from study sites.
Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.

Read the detailed description

This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program. Project implementation will occur at Guilford Avenue, the primary intake unit for Baltimore City Community Supervision (Probation and Parole). The proposed study is a parallel two-group randomized controlled trial in which 160 men and 160 women with OUD on community supervision in Baltimore will be randomly assigned within community supervision status (probation or parole) and gender to one of two treatment conditions: (1) Buprenorphine Bridge Treatment (BBT): Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment; or (2) Treatment as Usual (TAU): Participants will receive a referral to buprenorphine treatment in the community. Both conditions will receive information on overdose prevention. Participants will be assessed at baseline, and 1, 2, 3, 6, and 12 months post-intake using a comprehensive assessment battery. The Primary Aim: To compare the relative effectiveness of BBT to TAU in terms of: (a) illicit opioid drug test (oral saliva) results. The Secondary Aim: To examine the extent to which BBT is superior to TAU in terms of: (b) number of days receiving opioid treatment; (c) number of days using illicit opioids; (d) quality of life (i. physical health; ii. mental health); (e) HIV risk behaviors (i. sexual behavior; ii. needle use or sharing); (f) criminal activity; (g) re-arrest; and (h) re-incarceration. The proposed study is significant because the large number of probationers/parolees with OUD have limited access to an efficacious treatment, buprenorphine pharmacotherapy. The proposed study is innovative because it would be the first trial in the US assessing the effectiveness of interim buprenorphine initiated at a community supervision office compared to referral to a community treatment program. The public health impact would be widespread, as this model of care could be scaled-up throughout many areas of the US with criminal justice populations with high rates of OUD.

02

Conditions studied

  • Opioid Use
03

In context

Lead sponsor

Friends Research Institute, Inc. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must provide written prior to the conduct of any study-related procedures
  2. Male or female, 18-65 years of age, inclusive
  3. Be on parole or probation for at least the next 4 months
  4. Have a Baltimore City address, and (5) Primary diagnosis of () moderate-severe opioid use disorder (at least 4 symptoms) including current use and current physiologic dependence [Note: parolees not currently physically dependent will be allowed in the study].

Exclusion criteria

Exclusion Criteria:

  1. Current medical condition that may prevent the participant from safely participating in the study as determined by medical evaluation
  2. Current psychosis or suicidal ideation
  3. Cognitive disorders that prevent the participant from passing a study enrollment quiz
  4. Any pending legal action that would interrupt study participation (eg, pending incarceration, probation/parole revocation, unadjudicated charges)
  5. Exposure to any drug within 8 weeks of screening
  6. Current use benzodiazepines (such as Valium, Xanax and other sedatives), either prescribed or illicitly obtained
  7. Currently enrolled in a methadone maintenance treatment program or taking long-acting naltrexone.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Active comparator
    TAU

    Participants will receive a referral to buprenorphine treatment in the community.

    Other: Treatment as usual

  • Experimental
    BBT

    Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment

    Drug: Buprenorphine/Naloxone

Interventions

  • DrugBuprenorphine/Naloxone

    Drug pages: BuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NaloxoneStudies of NaloxoneNaloxone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment

    Also known as: BBT

  • OtherTreatment as usual

    Participants will receive a referral to buprenorphine treatment in the community

    Also known as: TAU

06

What researchers measure

Primary outcomes

  1. opioid use

    illicit opioid drug test (oral saliva) results

    Time frame: 12 months

Secondary outcomes

  1. treatment adherence

    entered community based treatment

    Time frame: 12 months

  2. treatment adherence

    number of days receiving opioid treatment

    Time frame: 12 months

  3. opioid use days

    number of days using illicit opioids

    Time frame: 12 months

  4. health-related quality of life

    physical health using the SF-12 Health Survey

    Time frame: 12 months

  5. health-related quality of life

    mental health using the SF-12 Health Survey

    Time frame: 12 months

  6. HIV risk behaviors

    sexual behavior using the Risk Assessment Battery (RAB)

    Time frame: 12 months

  7. HIV risk behaviors

    needle use or sharing using the Risk Assessment Battery (RB)

    Time frame: 12 months

  8. criminal activity

    criminal activity days

    Time frame: 12 months

  9. re-arrest

    time to re-arrest

    Time frame: 12 months

  10. re-incarceration

    time to re-incarceration

    Time frame: 12 months

07

Study locations

1 site
  • Division of Parole & Probation
    Baltimore, Maryland 21202, United States
08

References and documents

Individual participant data

Plan to share: Yes — FRI is committed to the open and timely dissemination of research outcomes. Investigators in the proposed activity recognize that promising new methods and strategies may arise during the course of the research. Fri will abide by the principles for sharing research resources as described by NIH in "Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources. Working with the research community, as well as the federal funding agency, FRI will serve the scientific community at large by sharing ideas and software to ensure that new knowledge benefits society. Our goals are to disseminate new ideas so the public can benefit from discoveries, and to generate new ideas for research and education. Any data shared will be de-identified and follow the regulations set forth in applicable Human Subjects Protection Guidelines.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: At completion of the study.

Access criteria: Contact Dr. Michael Gordon Friends Research Institute

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2022 to primary completion in Jan 2026, 42 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Aug 6, 2018
StartActual
Jul 1, 2022
Primary completionActual
Jan 30, 2026was Aug 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Jan 30, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Aug 31, 2026→Jan 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03616236
Lead sponsor
Friends Research Institute, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2018
Start date
Jul 1, 2022
Primary completion
Jan 30, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buprenorphine · Naloxone

Start the discussion